Peptide Comparison
Follistatin vs Follistatin 344
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Follistatin has stronger documented evidence (Preclinical + Gene Therapy Trials) than Follistatin 344 (Preclinical) while both occupy the myostatin-inhibitor class. When clinical-evidence tier is the deciding factor, Follistatin is the safer pick. Follistatin 344 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Follistatin | Follistatin 344 | |
|---|---|---|
| Class | Myostatin-binding glycoprotein; anabolic | Follistatin isoform; anabolic |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | Binds and neutralizes myostatin and activin; promotes muscle growth | Tissue-bound follistatin precursor; local myostatin inhibition |
| Route | SC injection | SC injection |
| Half-life | Variable by isoform | ~hours |
| Dosage (research) | 100-500 mcg SC daily (research) | 100-500 mcg SC daily |
| Evidence tier | Preclinical + Gene Therapy Trials | Preclinical |
| Research depth | 273 indexed | 32 indexed |
| Availability | Research Chemical | Research Chemical |
| Reported risks | Activin off-target effects; fertility concerns; limited human data | Same as Follistatin; limited data |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Follistatin or Follistatin 344?
Follistatin has stronger documented evidence (Preclinical + Gene Therapy Trials) than Follistatin 344 (Preclinical) while both occupy the myostatin-inhibitor class. When clinical-evidence tier is the deciding factor, Follistatin is the safer pick. Follistatin 344 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between Follistatin and Follistatin 344?
Follistatin is classed as Myostatin-binding glycoprotein; anabolic; Follistatin 344 is classed as Follistatin isoform; anabolic. Reported mechanism: Follistatin, Binds and neutralizes myostatin and activin; promotes muscle growth; Follistatin 344, Tissue-bound follistatin precursor; local myostatin inhibition. Reported half-life: Follistatin, Variable by isoform; Follistatin 344, ~hours. Routes in published studies: Follistatin, SC injection; Follistatin 344, SC injection.
Which has stronger evidence, Follistatin or Follistatin 344?
Follistatin and Follistatin 344 sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Follistatin is graded Preclinical + Gene Therapy Trials, with 20 cited sources on its reference page and 273 indexed studies. Follistatin 344 is graded Preclinical, with 2 cited sources on its reference page and 32 indexed studies.
Which is more accessible, Follistatin or Follistatin 344?
Neither Follistatin nor Follistatin 344 is an FDA-approved drug. Catalog status: Follistatin, Research Chemical; Follistatin 344, Research Chemical.
Are Follistatin and Follistatin 344 ever combined?
Follistatin and Follistatin 344 appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…